Précisez une action ou une cryptomonnaie dans la barre de recherche pour obtenir un récapitulatif
Oramed Pharmaceuticals Inc
OJU1Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York. Address: 1185 Avenue of the Americas, New York, NY, United States, 10036
Analytics
Objectif de Cours de WallStreet
3.25 USDRatio C/B
4.549Rendement du dividende
–Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Chiffres clés OJU1
Analyse des dividendes OJU1
Croissance des dividendes sur 5 ans
–Croissance continue
–Ratio de distribution Moyenne sur 5 ans
–Historique des dividendes OJU1
Valorisation des titres OJU1
financières OJU1
Résultats | 2019 | Dynamique |